Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML after an antecedent hematologic disorder and therapy related AML

Therapy related acute myeloid leukemia (tAML) and secondary AML after an antecedent hematologic disorder (sAML-AHD) are often addressed together, blurring any clinical and prognostic differences. Among 516 AML patients, we compared characteristics and outcomes of 149 patients with “sAML” (sAML-AHD: 104, tAML: 45), uniformly and intensively treated during the last 2 decades at one center. Clinical outcomes of the whole “sAML” cohort were significantly inferior compared to de novo AML and in both intermediate and poor cytogenetic risk groups.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2021 Category: Hematology Authors: Chrysavgi Lalayanni, Eleni Gavriilaki, Anastasia Athanasiadou, Michael Iskas, Maria Papathanasiou, Anastasia Marvaki, Sotiria Mpesikli, Giorgos Papaioannou, Despina Mallouri, Ioannis Batsis, Apostolia Papalexandri, Ioanna Sakellari, Achilles Anagnostopoul Source Type: research